J Craig Nelson

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, 401 Parnassus Avenue, Box 0984 5, San Francisco, CA 94143, USA
    Biol Psychiatry 55:296-300. 2004
  2. doi request reprint Baseline patient characteristics associated with placebo remission and their impact on remission with duloxetine and selected SSRI antidepressants
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA
    Curr Med Res Opin 29:827-33. 2013
  3. doi request reprint Moderators of outcome in late-life depression: a patient-level meta-analysis
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, USA
    Am J Psychiatry 170:651-9. 2013
  4. doi request reprint Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy
    James Craig Nelson
    Department of Psychiatry, University of California San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA
    Int Clin Psychopharmacol 27:125-33. 2012
  5. doi request reprint Predictors of remission with placebo using an integrated study database from patients with major depressive disorder
    J C Nelson
    Department of Psychiatry, University of California, San Francisco, CA 94143, USA
    Curr Med Res Opin 28:325-34. 2012
  6. ncbi request reprint Suicidal thinking and behavior during treatment with sertraline in late-life depression
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, San Franciso, CA, USA
    Am J Geriatr Psychiatry 15:573-80. 2007
  7. doi request reprint Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, CA, USA
    Am J Geriatr Psychiatry 16:558-67. 2008
  8. doi request reprint A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, San Francisco, California, USA
    J Am Geriatr Soc 59:577-85. 2011
  9. doi request reprint Anxiety does not predict response to antidepressant treatment in late life depression: results of a meta-analysis
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, CA, USA
    Int J Geriatr Psychiatry 24:539-44. 2009
  10. doi request reprint Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies
    J Craig Nelson
    University of California, San Francisco, California, USA
    J Affect Disord 120:133-40. 2010

Detail Information

Publications33

  1. ncbi request reprint Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, 401 Parnassus Avenue, Box 0984 5, San Francisco, CA 94143, USA
    Biol Psychiatry 55:296-300. 2004
    ..The current study was undertaken as a proof of the concept that combining norepinephrine and serotonin reuptake inhibition would be more effective and act more rapidly than either drug alone...
  2. doi request reprint Baseline patient characteristics associated with placebo remission and their impact on remission with duloxetine and selected SSRI antidepressants
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA
    Curr Med Res Opin 29:827-33. 2013
    ....
  3. doi request reprint Moderators of outcome in late-life depression: a patient-level meta-analysis
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, USA
    Am J Psychiatry 170:651-9. 2013
    ..The authors sought to identify factors that moderate outcome in late-life major depression and that identify patients for whom antidepressants have clinically meaningful effects...
  4. doi request reprint Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy
    James Craig Nelson
    Department of Psychiatry, University of California San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA
    Int Clin Psychopharmacol 27:125-33. 2012
    ..12%, respectively, P<0.0001). The numbers needed to treat with aripiprazole+ADT were six for response and eight for remission. Aripiprazole augmentation had a rapid and clinically meaningful effect in ADT minimal responders...
  5. doi request reprint Predictors of remission with placebo using an integrated study database from patients with major depressive disorder
    J C Nelson
    Department of Psychiatry, University of California, San Francisco, CA 94143, USA
    Curr Med Res Opin 28:325-34. 2012
    ..To identify predictors of remission with placebo treatment in double-blind randomized controlled trials (RCTs) in major depressive disorder (MDD)...
  6. ncbi request reprint Suicidal thinking and behavior during treatment with sertraline in late-life depression
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, San Franciso, CA, USA
    Am J Geriatr Psychiatry 15:573-80. 2007
    ..To determine effects of sertraline on suicidal thinking and behavior in patients with late-life major depression...
  7. doi request reprint Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, CA, USA
    Am J Geriatr Psychiatry 16:558-67. 2008
    ..This systematic review and meta-analysis was undertaken to assess the evidence for efficacy of second-generation antidepressants in late-life major depression...
  8. doi request reprint A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, San Francisco, California, USA
    J Am Geriatr Soc 59:577-85. 2011
    ..To determine the efficacy of antidepressants in people with depression and dementia...
  9. doi request reprint Anxiety does not predict response to antidepressant treatment in late life depression: results of a meta-analysis
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, CA, USA
    Int J Geriatr Psychiatry 24:539-44. 2009
    ..Our aim was to determine if anxiety predicts antidepressant response in previously identified placebo-controlled trials of second generation antidepressants for late-life depression...
  10. doi request reprint Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies
    J Craig Nelson
    University of California, San Francisco, California, USA
    J Affect Disord 120:133-40. 2010
    ..The objective of this study was to examine the effects of aripiprazole on core symptoms of depression...
  11. doi request reprint Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, 401 Parnassus Ave, Box 0984 F, San Francisco, CA 94143, USA
    Am J Psychiatry 166:980-91. 2009
    ..The authors sought to determine by meta-analysis the efficacy and tolerability of adjunctive atypical antipsychotic agents in major depressive disorder...
  12. doi request reprint Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials
    J Craig Nelson
    Department of Psychiatry, University of California, San Francisco, California, USA
    Depress Anxiety 27:12-8. 2010
    ..The objective of this study is to determine whether specific antidepressant effects, estimated by drug-placebo differences, are reduced in anxious depression during treatment of MDD with duloxetine...
  13. pmc Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163)
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA
    Prim Care Companion J Clin Psychiatry 11:344-52. 2009
    ..To evaluate the safety and tolerability of aripiprazole adjunctive to standard antidepressant therapy (ADT) for patients with major depressive disorder (DSM-IV-TR criteria)...
  14. ncbi request reprint Are there predictors of outcome in depressed elderly nursing home residents during treatment with mirtazapine orally disintegrating tablets?
    J Craig Nelson
    University California San Francisco, San Francisco, CA, USA
    Int J Geriatr Psychiatry 22:999-1003. 2007
    ..Treatment studies of depression in residential care are limited. Reports of predictors of response are rare. In the largest nursing home prospective antidepressant trial reported, we examined predictors of response...
  15. pmc The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials
    J Craig Nelson
    Department of Psychiatry, University of California at San Francisco, San Francisco, CA, USA
    Prim Care Companion J Clin Psychiatry 8:212-9. 2006
    ..8%; paroxetine, 13.8%; placebo, 3.1%), but the active-treatment groups did not differ. Conclusions: Duloxetine is safe and well tolerated in patients with MDD, with safety and tolerability comparable to that of paroxetine...
  16. ncbi request reprint Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, San Francisco, California 94143, USA
    Biol Psychiatry 57:1535-42. 2005
    ....
  17. ncbi request reprint Symptoms of late-life depression: frequency and change during treatment
    J Craig Nelson
    Dept of Psychiatry, University of California at San Francisco, 401 Parnassus Ave, Box 0984 F, San Francisco, CA 94143, USA
    Am J Geriatr Psychiatry 13:520-6. 2005
    ....
  18. ncbi request reprint Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, 401 Parnassus Avenue, PO Box 0984 F, San Francisco, CA 94143, USA
    J Clin Psychiatry 66:1409-14. 2005
    ..We examined the frequency and severity of residual depressive symptoms in 2 studies comparing the selective serotonin reuptake inhibitor (SSRI) fluoxetine with the norepinephrine reuptake inhibitor (NRI) reboxetine...
  19. ncbi request reprint Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older
    J Craig Nelson
    Department of Psychiatry, University of California, San Francisco, USA
    Int J Geriatr Psychiatry 21:898-901. 2006
    ..The naturalistic conditions of the study allowed us to include patients with cognitive impairment, concomitant medications and comorbid illness...
  20. ncbi request reprint Assessment of outcome in depression
    J Craig Nelson
    Department of Psychiatry, University of California, San Francisco, CA, USA
    J Psychopharmacol 20:47-53. 2006
    ..And we review studies that have identified 'core' symptoms of depression and compare these findings to the magnitude of individual symptom change we found in five studies of selective serotonergic or nonadrenergic antidepressants...
  21. pmc Serum BDNF levels before treatment predict SSRI response in depression
    Owen M Wolkowitz
    Department of Psychiatry, University of California, San Francisco School of Medicine, San Francisco, CA 94143, United States
    Prog Neuropsychopharmacol Biol Psychiatry 35:1623-30. 2011
    ..It is also unknown whether pre-treatment serum BDNF levels predict antidepressant response...
  22. ncbi request reprint A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WAC 812 Boston, MA 02114, USA
    Eur Neuropsychopharmacol 18:122-7. 2008
    ..These results suggest that the NRI reboxetine and the SSRIs differ with respect to their side-effect profile and overall tolerability but not their efficacy in treating MDD...
  23. ncbi request reprint Duloxetine for the treatment of major depressive disorder in older patients
    J Craig Nelson
    Department of Psychiatry, University of California at San Francisco, San Francisco, CA, USA
    Am J Geriatr Psychiatry 13:227-35. 2005
    ..The efficacy and safety of duloxetine, a dual reuptake inhibitor of serotonin (5-HT) and norepinephrine (NE), were evaluated in the treatment of major depressive disorder (MDD) and associated pain symptoms in patients age 55 and older...
  24. ncbi request reprint Are antidepressants effective? What's a clinician to think?
    J Craig Nelson
    University of California, San Francisco, USA
    J Clin Psychiatry 69:1014-5. 2008
  25. ncbi request reprint Augmentation and combination strategies in resistant depression
    J Craig Nelson
    Department of Psychiatry, University of California School of Medicine, San Francisco, CA, USA
    J Clin Psychiatry 70:e20. 2009
    ..Clinical trials have assessed the efficacy of many agents commonly used for augmentation or combination therapy, but well-designed, large trials with a clear definition of treatment resistance are needed...
  26. ncbi request reprint Managing treatment-resistant major depression
    J Craig Nelson
    Department of Psychiatry, University of California, San Francisco 94143 0984, USA
    J Clin Psychiatry 64:5-12. 2003
    ..More research is needed that controls for continued time on the initial agent, that compares different strategies, and that determines which patients are the best candidates for which treatment...
  27. pmc Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress--preliminary findings
    Owen M Wolkowitz
    Department of Psychiatry, University of California San Francisco School of Medicine, San Francisco, California, United States of America
    PLoS ONE 6:e17837. 2011
    ..We sought to determine if leukocyte telomeres are shortened in Major Depressive Disorder (MDD), whether this is a function of lifetime depression exposure and whether this is related to putative mediators, oxidation and inflammation...
  28. ncbi request reprint Augmentation strategies in the treatment of major depressive disorder. Recent findings and current status of augmentation strategies
    J Craig Nelson
    Department of Psychiatry, University of California, San Francisco, USA
    CNS Spectr 12:6-9. 2007
  29. ncbi request reprint Increased risk of cerebrovascular adverse events and death in elderly demented patients treated with atypical antipsychotics: what's a clinician to do?
    J Craig Nelson
    University of California, San Francisco, USA
    J Clin Psychiatry 66:1071. 2005
  30. ncbi request reprint Psychotic depression and mortality
    Meena Vythilingam
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    Am J Psychiatry 160:574-6. 2003
    ..The authors hypothesized that patients with psychotic depression would have higher mortality rates than patients with nonpsychotic depression...
  31. pmc Augmentation treatment in major depressive disorder: focus on aripiprazole
    J Craig Nelson
    University of California San Francisco, San Francisco, California, USA
    Neuropsychiatr Dis Treat 4:937-48. 2008
    ..The availability of this new treatment option should allow more patients with MDD to achieve remission and, ultimately, long-term, successful outcomes...
  32. ncbi request reprint Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depression
    Joseph F Cubells
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06516, USA
    Biol Psychiatry 51:358-64. 2002
    ..Plasma DbetaH is under genetic control by the structural locus encoding DbetaH protein, DBH. This study tested the hypothesis that diagnosis-specific allelic variation at DBH accounts for lower plasma DbetaH in UDPF...
  33. ncbi request reprint Assessment and treatment of depression in disability claimants: a cost-benefit simulation study
    Andrew C Leon
    Weill Medical College of Cornell University, Department of Psychiatry, New York, New York 10021, USA
    J Nerv Ment Dis 190:3-9. 2002
    ..The economic and public health benefits both point toward the value of such an intervention for disability claimants...